GB201321736D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
GB201321736D0
GB201321736D0 GBGB1321736.9A GB201321736A GB201321736D0 GB 201321736 D0 GB201321736 D0 GB 201321736D0 GB 201321736 A GB201321736 A GB 201321736A GB 201321736 D0 GB201321736 D0 GB 201321736D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1321736.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma SA
Original Assignee
UCB Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Pharma SA filed Critical UCB Pharma SA
Priority to GBGB1321736.9A priority Critical patent/GB201321736D0/en
Publication of GB201321736D0 publication Critical patent/GB201321736D0/en
Priority to BR112016011484A priority patent/BR112016011484A2/en
Priority to EP14808640.8A priority patent/EP3080127B1/en
Priority to RU2016127438A priority patent/RU2691629C1/en
Priority to US15/100,690 priority patent/US9932342B2/en
Priority to PCT/EP2014/076836 priority patent/WO2015086499A1/en
Priority to CN201480067063.7A priority patent/CN105814059B/en
Priority to ES14808640T priority patent/ES2817051T3/en
Priority to JP2016537566A priority patent/JP6495918B2/en
Priority to CA2931019A priority patent/CA2931019C/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
GBGB1321736.9A 2013-12-09 2013-12-09 Therapeutic agents Ceased GB201321736D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1321736.9A GB201321736D0 (en) 2013-12-09 2013-12-09 Therapeutic agents
CA2931019A CA2931019C (en) 2013-12-09 2014-12-08 Imidazopyrimidine derivatives as modulators of tnf activity
US15/100,690 US9932342B2 (en) 2013-12-09 2014-12-08 Imidazopyrimidine derivatives as modulators of TNF activity
EP14808640.8A EP3080127B1 (en) 2013-12-09 2014-12-08 Imidazopyrimidine derivatives as modulators of tnf activity
RU2016127438A RU2691629C1 (en) 2013-12-09 2014-12-08 Imidazopyrimidine derivatives as modulators of tnf activity
BR112016011484A BR112016011484A2 (en) 2013-12-09 2014-12-08 IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY
PCT/EP2014/076836 WO2015086499A1 (en) 2013-12-09 2014-12-08 Imidazopyrimidine derivatives as modulators of tnf activity
CN201480067063.7A CN105814059B (en) 2013-12-09 2014-12-08 Imidazo pyrimidine derivatives as TNF active regulators
ES14808640T ES2817051T3 (en) 2013-12-09 2014-12-08 Imidazopyrimidine derivatives as modulators of TNF activity
JP2016537566A JP6495918B2 (en) 2013-12-09 2014-12-08 Imidazo pyrimidine derivatives as modulators of TNF activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1321736.9A GB201321736D0 (en) 2013-12-09 2013-12-09 Therapeutic agents

Publications (1)

Publication Number Publication Date
GB201321736D0 true GB201321736D0 (en) 2014-01-22

Family

ID=50000419

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1321736.9A Ceased GB201321736D0 (en) 2013-12-09 2013-12-09 Therapeutic agents

Country Status (10)

Country Link
US (1) US9932342B2 (en)
EP (1) EP3080127B1 (en)
JP (1) JP6495918B2 (en)
CN (1) CN105814059B (en)
BR (1) BR112016011484A2 (en)
CA (1) CA2931019C (en)
ES (1) ES2817051T3 (en)
GB (1) GB201321736D0 (en)
RU (1) RU2691629C1 (en)
WO (1) WO2015086499A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321735D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CA2944697C (en) 2014-04-22 2022-07-19 Universitaet Basel Manufacturing process for triazine, pyrimidine and pyridine derivatives
TWI713497B (en) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
WO2016168638A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
US9856253B2 (en) 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling
TW201706258A (en) 2015-04-17 2017-02-16 艾伯維有限公司 Indazolones as modulators of TNF signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
MA52119A (en) 2015-10-19 2018-08-29 Ncyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
JP7148401B2 (en) 2015-11-19 2022-10-05 インサイト・コーポレイション Heterocyclic compounds as immunomodulators
SI3394033T1 (en) 2015-12-22 2021-03-31 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2018016273A (en) 2016-06-20 2019-07-04 Incyte Corp Heterocyclic compounds as immunomodulators.
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112019012993A2 (en) 2016-12-22 2019-12-03 Incyte Corp benzo-oxazole derivatives as immunomodulators
HUE060233T2 (en) 2016-12-22 2023-02-28 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
KR20200088397A (en) 2017-11-14 2020-07-22 칠드런'즈 메디컬 센터 코포레이션 New imidazopyrimidine compounds and uses thereof
JP7382316B2 (en) * 2017-11-14 2023-11-16 ザ チルドレンズ メディカル センター コーポレーション Use of imidazopyrimidines to modulate human immune responses
SI3774791T1 (en) 2018-03-30 2023-04-28 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE061503T2 (en) 2018-05-11 2023-07-28 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
JP2022544189A (en) 2019-08-09 2022-10-17 インサイト・コーポレイション Salts of PD-1/PD-L1 inhibitors
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (en) 2019-11-11 2022-10-11 Incyte Corp SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR
TW202233615A (en) 2020-11-06 2022-09-01 美商英塞特公司 Crystalline form of a pd-1/pd-l1 inhibitor
AR124001A1 (en) 2020-11-06 2023-02-01 Incyte Corp PROCESS FOR MANUFACTURING A PD-1 / PD-L1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOF
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920702621A (en) * 1989-06-13 1992-10-06 스튜어트 알. 슈터 Inhibition of Interleukin-1 or Tumor Factor Factor Production by Monocytes and / or Macrophages
JP4025468B2 (en) * 1999-07-29 2007-12-19 三井化学株式会社 Organic electroluminescence device
JP2003513977A (en) * 1999-11-10 2003-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Substituted 2-aryl-3- (heteroaryl) -imidazo [1,2-α] pyrimidines and related pharmaceutical compositions and methods
CA2397661C (en) 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
AU2002230098B2 (en) * 2001-01-30 2007-06-14 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and cognitive enhancers comprising the same as effective components
CA2450555A1 (en) * 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
GB0128499D0 (en) * 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
BRPI0512261A (en) * 2004-06-17 2008-02-26 Wyeth Corp Gonadotropin-releasing hormone receptor antagonists
US20060252807A1 (en) * 2005-04-22 2006-11-09 Kalypsys, Inc. Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
US20090156617A1 (en) * 2005-05-12 2009-06-18 Northrup Alan B Tyrosine kinase inhibitors
EP1891042B1 (en) * 2005-06-01 2013-10-02 UCB Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their therapeutic use on the central nervous system
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
JP2009518409A (en) * 2005-12-06 2009-05-07 メルク エンド カムパニー インコーポレーテッド Morpholine carboxamide prokineticin receptor antagonist
WO2007096764A2 (en) * 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
GEP20125658B (en) * 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
NZ602832A (en) * 2008-07-14 2014-04-30 Gilead Sciences Inc Fused heterocyclic hdac inhibitor compounds
EP2467383A1 (en) * 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
CN103189379A (en) 2010-07-13 2013-07-03 拜耳知识产权有限责任公司 Bicyclic pyrimidines
KR101375361B1 (en) * 2010-12-30 2014-03-27 (주)씨에스엘쏠라 Organic light compound and organic light device using the same
US9000186B2 (en) * 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
CN103874697A (en) * 2011-08-03 2014-06-18 协和发酵麒麟株式会社 Dibenzooxepin derivative
WO2013036676A1 (en) * 2011-09-06 2013-03-14 New York Blood Center, Inc. Hiv inhibitors
ES2675583T3 (en) 2012-06-11 2018-07-11 Ucb Biopharma Sprl TNF-alpha benzimidazoles modulators
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
ES2689429T3 (en) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
WO2015030847A1 (en) * 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors

Also Published As

Publication number Publication date
BR112016011484A2 (en) 2017-08-08
JP2016539982A (en) 2016-12-22
CA2931019C (en) 2021-10-26
CA2931019A1 (en) 2015-06-18
ES2817051T3 (en) 2021-04-06
RU2016127438A (en) 2018-01-23
EP3080127A1 (en) 2016-10-19
WO2015086499A1 (en) 2015-06-18
EP3080127B1 (en) 2020-06-24
RU2691629C1 (en) 2019-06-17
CN105814059A (en) 2016-07-27
US9932342B2 (en) 2018-04-03
CN105814059B (en) 2018-04-03
US20160297827A1 (en) 2016-10-13
JP6495918B2 (en) 2019-04-03

Similar Documents

Publication Publication Date Title
IL263026A (en) Ibrutinib combination therapy
GB201321746D0 (en) Therapeutic agents
GB201321743D0 (en) Therapeutic agents
GB201321736D0 (en) Therapeutic agents
GB201321729D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321738D0 (en) Therapeutic Agents
GB201321728D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
GB201321741D0 (en) Therapeutic agents
GB201321740D0 (en) Therapeutic agents
GB201321732D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321737D0 (en) Therapeutic Agents
GB201321744D0 (en) Therapeutic agents
GB201321742D0 (en) Therapeutic agents
GB201321735D0 (en) Therapeutic Agents
GB201321745D0 (en) Therapeutic agents
GB201321731D0 (en) Therapeutic agents
GB201308440D0 (en) Therapeutic
GB201321748D0 (en) Therapeutic agents
GB201321749D0 (en) Therapeutic agents
GB201310755D0 (en) Therapy
GB201318668D0 (en) Sonosensitive therapeutic

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)